Contributions
Abstract: P867
Type: Poster
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Cognitive impairment is common in patients with Multiple Sclerosis (PwMS). Cognitive impairment in PwMS can impact employment, driving, fall risk, Quality of Life (QoL). Cognitive impairment may be present and vary independently of EDSS or changes in EDSS. Few studies to date assessed the evolution of cognitive function over time in PwMS.
Objective: To explore how cognitive function changes over time in a large cohort of PwMS.
Methods: PwMS completed a standardized computerized cognitive assessment battery (NeuroTrax) with analysis of cognitive domain scores (memory, executive function, visual spatial, verbal function, attention, information processing, motor skills). The average of these domain scores was defined: global cognitive score (GCS). NeuroTrax domain scores are normalized to an IQ-style scale (mean: 100, SD: 15) in an age- and education-specific fashion by comparing the subject"s specific achievements to normative data of individuals classified as cognitively healthy. Cognitive domain score < 85 was considered impaired. This procedure was repeated after a time interval of 2-52 months, for each patient.
Results: There were 369 test-retest pairs from 282 individuals with MS [Female: 220 (78%), EDSS 2.6±1.9, Education years: 15±2.8]. The average change in GCS was 2±7.3, implying that 70% of the re-test results remained stable within ±0.5SD from initial scores. The average number of impaired cognitive domains on initial testing was 1.4±1.9. 180 (48.85) test-retest pairs had no change in the number of impaired domains, the others had either increased or decreased number of impaired cognitive domains upon re-test (range: 1-6).
Conclusion: Changes in cognitive function with time of PwMS were detected by NeuroTrax. The clinical significance of these changes and their relationship to MS disease activity and treatment are being elucidated. This method of objective examiner independent analysis might provide information relevant to patient care as an adjunct to EDSS and MRI.
Disclosure: Glen Doniger is an employee of NeuroTrax Corporation
Abstract: P867
Type: Poster
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Cognitive impairment is common in patients with Multiple Sclerosis (PwMS). Cognitive impairment in PwMS can impact employment, driving, fall risk, Quality of Life (QoL). Cognitive impairment may be present and vary independently of EDSS or changes in EDSS. Few studies to date assessed the evolution of cognitive function over time in PwMS.
Objective: To explore how cognitive function changes over time in a large cohort of PwMS.
Methods: PwMS completed a standardized computerized cognitive assessment battery (NeuroTrax) with analysis of cognitive domain scores (memory, executive function, visual spatial, verbal function, attention, information processing, motor skills). The average of these domain scores was defined: global cognitive score (GCS). NeuroTrax domain scores are normalized to an IQ-style scale (mean: 100, SD: 15) in an age- and education-specific fashion by comparing the subject"s specific achievements to normative data of individuals classified as cognitively healthy. Cognitive domain score < 85 was considered impaired. This procedure was repeated after a time interval of 2-52 months, for each patient.
Results: There were 369 test-retest pairs from 282 individuals with MS [Female: 220 (78%), EDSS 2.6±1.9, Education years: 15±2.8]. The average change in GCS was 2±7.3, implying that 70% of the re-test results remained stable within ±0.5SD from initial scores. The average number of impaired cognitive domains on initial testing was 1.4±1.9. 180 (48.85) test-retest pairs had no change in the number of impaired domains, the others had either increased or decreased number of impaired cognitive domains upon re-test (range: 1-6).
Conclusion: Changes in cognitive function with time of PwMS were detected by NeuroTrax. The clinical significance of these changes and their relationship to MS disease activity and treatment are being elucidated. This method of objective examiner independent analysis might provide information relevant to patient care as an adjunct to EDSS and MRI.
Disclosure: Glen Doniger is an employee of NeuroTrax Corporation